Literature DB >> 8575854

Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides.

P Jachimczak1, B Hessdörfer, K Fabel-Schulte, C Wismeth, W Brysch, K H Schlingensiepen, A Bauer, A Blesch, U Bogdahn.   

Abstract

Transforming growth factors-beta 1 and -beta 2 (TGF-beta 1 and -beta 2) are important growth-regulatory proteins for astroglial neoplasms. We analyzed their role in tumor-cell proliferation in 12 glioma cell lines, employing phosphorothioate antisense oligodeoxynucleotides (S-ODNs, 14 mer), specifically targeted against the coding sequences of TGF-beta 1-mRNA and TGF-beta 2-mRNA. TGF-beta 1-S-ODNs inhibited cell proliferation in 5 of 12 gliomas, whereas TGF-beta 2-S-ODNs reduced the cell proliferation in all glioma cell lines, compared to nonsense-S-ODN-treated and S-ODN-untreated cells as controls. The efficacy and specificity of antisense effects was validated by Northern-blot analysis and determination of protein concentrations in culture supernatants (ELISA). Exogenous hrTGF-beta 1 either stimulated or inhibited the cell lines, whereas pnTGF-beta 2 stimulated the proliferation of most glioma cells. Blocking the extracellular pathway of TGF-beta by neutralizing antibodies only slightly inhibited those cell lines, which were markedly stimulated by TGF-betas. As the effects of TGF-beta 2-S-ODNs were much stronger than those of TGF-beta neutralizing antibodies, we postulate that the endogenously produced TGF-beta 2 control glioma-cell proliferation, in part by an intracellular loop.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8575854     DOI: 10.1002/(SICI)1097-0215(19960126)65:3<332::AID-IJC10>3.0.CO;2-C

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

2.  Versican isoform V1 regulates proliferation and migration in high-grade gliomas.

Authors:  Julia Onken; Sylvia Moeckel; Petra Leukel; Verena Leidgens; Fusun Baumann; Ulrich Bogdahn; Arabel Vollmann-Zwerenz; Peter Hau
Journal:  J Neurooncol       Date:  2014-07-27       Impact factor: 4.130

3.  Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

Authors:  Mengxian Zhang; Tobias W Herion; Carmen Timke; Na Han; Kai Hauser; Klaus J Weber; Peter Peschke; Ute Wirkner; Michael Lahn; Peter E Huber
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

Review 4.  Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

5.  TGF-β1 promotes motility and invasiveness of glioma cells through activation of ADAM17.

Authors:  Yong Lu; Feng Jiang; Xuguang Zheng; Mark Katakowski; Benjamin Buller; Shing-Shun Tony To; Michael Chopp
Journal:  Oncol Rep       Date:  2011-02-24       Impact factor: 3.906

Review 6.  Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.

Authors:  Nolan Ung; Isaac Yang
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

7.  Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

Authors:  Thomas Schneider; Michael Sailer; Siegfried Ansorge; Raimund Firsching; Dirk Reinhold
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

8.  Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells.

Authors:  Janka Held-Feindt; Björn Lütjohann; Hendrik Ungefroren; Hubertus M Mehdorn; Rolf Mentlein
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

Review 9.  Therapeutic targets in malignant glioblastoma microenvironment.

Authors:  Mary Helen Barcellos-Hoff; Elizabeth W Newcomb; David Zagzag; Ashwatha Narayana
Journal:  Semin Radiat Oncol       Date:  2009-07       Impact factor: 5.934

Review 10.  Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Authors:  Lee A Selznick; Mohammed F Shamji; Peter Fecci; Matthias Gromeier; Allan H Friedman; John Sampson
Journal:  Neurosurg Rev       Date:  2008-02-08       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.